SecBot SecBot
PRESS-RELEASE ·Filed May 22, 2026

ABVX

Abivax
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The near-term binary catalyst is the ABTECT Phase 3 UC maintenance top-line data, expected within ~4-6 weeks. Positive data would de-risk NDA submission pathway and likely drive a re-rating. Failure would significantly impair the asset's value. The cash position through Q4 2027 is sufficient to cover ongoing operations and clinical programs through key milestones, including the Phase 3 readout.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$126.41
T+0 close · May 22, 2026 · via day close
Latest settled
−4.63%
T+60 · $120.56
Vs SPY
−7.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $126.41entry
  2. T+1 · 6mo ago +2.94%α +2.99% · $130.13
  3. T+5 · 6mo ago +2.59%α +1.51% · $129.69
  4. T+20 · 5mo ago −25.63%α −23.68% · $94.01
  5. T+60 · 3mo ago −4.63%α −7.35% · $120.56
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abivax reported Q1 2026 net loss of €48.5M (vs €52.4M loss in Q1 2025) with operating loss of €56.2M. The press release highlights durable Phase 2 clinical remission data (68% at week 144 on 25mg de-escalation) and €491.6M cash runway into Q4 2027. The company is pre-revenue with a biotech pipeline catalyst, the ABTECT Phase 3 UC maintenance trial top-line results due late Q2 2026 is the near-term binary event.

Key Facts

  • Operational loss of €56.2M in Q1 2026 vs €47.2M in Q1 2025
  • Net loss of €48.5M vs €52.4M year-over-year (improved by financial gain)
  • Cash, cash equivalents and short-term investments of €491.6M as of March 31, 2026
  • Cash runway projected into Q4 2027
  • Phase 3 ABTECT-UC maintenance trial top-line results expected late Q2 2026
  • 130 patients de-escalated to 25mg obefazimod; 68% in clinical remission at week 144 (ITT)
  • NDA submission for obefazimod in UC planned for Q4 2026 (subject to positive data)
  • Phase 2b CD induction trial top-line results expected Q4 2026
  • R&D spend increased 26% YoY to €49.5M, driven by new indications and CD program
  • Equity offering of $45M (€38.5M) ADS completed May 5, 2026

Financial Impact

Pre-revenue clinical biotech, no revenue to evaluate. Q1 2026 operating loss €56.2M vs €47.2M in Q1 2025; net loss improved by financial gain (€8.0M vs -€5.2M). Cash burn from operations was €50.5M in Q1 2026 vs €33.3M in Q1 2025.

cash runwayoperating lossR&D spend

Risk Factors

  • Phase 3 ABTECT-UC maintenance trial may fail to meet endpoints, binary risk for the stock near-term
  • Pre-revenue stage with high cash burn rate (€50.5M operating cash outflow in Q1 2026)
  • Dilution risk from ADS offering completed May 5, 2026 ($45M)
  • Regulatory and commercial execution risk for obefazimod in UC and CD indications

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3300344

Track record

10 reports on ABVX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.05% at T+60 after the Jul 2, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $83.40 Now $83.61 +0.25% settles Nov 24
  2. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $86.59 to $85.73 Now $83.61 −3.44% ▼ −0.99% +1.71% vs SPY
  3. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $130.00 to $121.45 Now $83.61 −35.68% ▼ −6.58% −7.79% vs SPY
  4. Jul 2, 202619w ago 6-K Bearish 6/10 Entry $144.65 to $140.74 Now $83.61 +42.20% ▲ +2.70% +3.63% vs SPY
  5. Jul 2, 202619w ago 424B5 Bearish 6/10 Entry $144.65 to $140.74 Now $83.61 +42.20% ▲ +2.70% +3.63% vs SPY
  6. Jul 1, 202619w ago Press Release Bearish 6/10 Entry $132.56 to $142.17 Now $83.61 +36.93% ▼ −7.25% −6.99% vs SPY
  7. Jun 29, 202620w ago 6-K Bullish 7/10 Entry $133.26 to $143.99 Now $83.61 −37.26% ▲ +8.05% +7.45% vs SPY
  8. Jun 29, 202620w ago Press Release Bullish 7/10 Entry $133.26 to $143.99 Now $83.61 −37.26% ▲ +8.05% +7.45% vs SPY
  9. May 22, 202625w ago Press Release Neutral 5/10 Viewing Entry $126.41 to $129.69 Now $83.61 −33.86% ▲ +2.59% +1.51% vs SPY
  10. Mar 23, 202634w ago Press Release Mixed 6/10 Entry $110.17 to $111.35 Now $83.61 −24.11% ▲ +1.07% +1.49% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (13h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 22, 2026